Focused On-demand Library for Zinc finger protein ubi-d4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q92785

UPID:

REQU_HUMAN

Alternative names:

Apoptosis response zinc finger protein; BRG1-associated factor 45D; D4, zinc and double PHD fingers family 2; Protein requiem

Alternative UPACC:

Q92785; A8K7C9; B4DT58

Background:

Zinc finger protein ubi-d4, also known as Apoptosis response zinc finger protein, BRG1-associated factor 45D, D4, zinc and double PHD fingers family 2, and Protein requiem, plays a pivotal role in transcriptional regulation. It achieves this by binding to modified histones H3 and H4, acting as a negative regulator of myeloid differentiation in hematopoietic progenitor cells, and possibly influencing the development and maturation of lymphoid cells. Additionally, it is involved in the regulation of the non-canonical NF-kappa-B pathway.

Therapeutic significance:

Zinc finger protein ubi-d4 is implicated in Coffin-Siris syndrome 7, a genetic disorder characterized by intellectual disability, coarse facial features, and other systemic malformations. Understanding the role of Zinc finger protein ubi-d4 could open doors to potential therapeutic strategies for this syndrome.